En­gine Bio­sciences bags $27M Se­ries A ex­ten­sion to ad­vance pre­ci­sion med­i­cine plat­form in on­col­o­gy

En­gine Bio­sciences has raised $27 mil­lion in a Se­ries A ex­ten­sion with an eye to ad­vance its dis­cov­ery-stage pre­ci­sion on­col­o­gy pro­grams, which lever­age both ma­chine learn­ing and CRISPR screen­ing tech­nol­o­gy.

The ex­ten­sion raise was led by Po­laris Part­ners with sup­port from ex­ist­ing in­vestors Clavyst­Bio, In­vus and ED­BI, as well as new back­ers Coro­net Ven­tures and SEEDS Cap­i­tal. It brings the to­tal funds raised by the trans-Pa­cif­ic biotech since in­cep­tion to $86 mil­lion, in­clud­ing $70 mil­lion in to­tal Se­ries A pro­ceeds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER